These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14964752)

  • 1. Generalized pustular psoriasis following withdrawal of efalizumab.
    Gaylor ML; Duvic M
    J Drugs Dermatol; 2004; 3(1):77-9. PubMed ID: 14964752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized pustular psoriasis following withdrawal of short-term cyclosporin therapy for psoriatic arthritis.
    Hong SB; Kim NI
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):522-3. PubMed ID: 15987319
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential use of infliximab and etanercept in generalized pustular psoriasis.
    Weisenseel P; Prinz JC
    Cutis; 2006 Sep; 78(3):197-9. PubMed ID: 17036664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of adalimumab in generalized pustular psoriasis.
    Zangrilli A; Papoutsaki M; Talamonti M; Chimenti S
    J Dermatolog Treat; 2008; 19(3):185-7. PubMed ID: 18569276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
    Torii H; Nakagawa H;
    J Dermatol; 2011 Apr; 38(4):321-34. PubMed ID: 21544940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects.
    Firmin D; Roguedas AM; Lemasson G; Abgrall JF; Misery L
    Dermatology; 2008; 217(3):203-6. PubMed ID: 18594143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcorneal pustular dermatosis: a variant of pustular psoriasis.
    Sanchez N; Ackerman AB
    Acta Derm Venereol Suppl (Stockh); 1979; 59(85):147-51. PubMed ID: 294090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
    Fisher VS
    J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis.
    Zheng J; Gao Y; Ding Y
    Dermatol Ther; 2019 Nov; 32(6):e13132. PubMed ID: 31631466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in recalcitrant generalized pustular arthropatic psoriasis.
    Vieira Serrão V; Martins A; Lopes MJ
    Eur J Dermatol; 2008; 18(1):71-3. PubMed ID: 18086593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
    Lowes MA; Turton JA; Krueger JG; Barnetson RS
    BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efalizumab: a review of events reported during clinical trials and side effects.
    Scheinfeld N
    Expert Opin Drug Saf; 2006 Mar; 5(2):197-209. PubMed ID: 16503742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Course and Characteristics of Generalized Pustular Psoriasis.
    Choon SE; Navarini AA; Pinter A
    Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):21-29. PubMed ID: 35061227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A patient with psoriatic arthritis due to generalized pustular psoriasis (von Zumbusch type)].
    Seki K; Amano T; Nakayama Y
    Ryumachi; 1997 Aug; 37(4):568-73. PubMed ID: 9311283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.